Vojislav Pejović
About
Vojislav Pejović is a scholar working on Pharmacology, Psychiatry and Mental health and Physiology.
According to data from OpenAlex, Vojislav Pejović has authored 32 papers receiving a total of 531 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pharmacology, 8 papers in Psychiatry and Mental health and 5 papers in Physiology. Recurrent topics in Vojislav Pejović's work include Cholinesterase and Neurodegenerative Diseases (11 papers), Dementia and Cognitive Impairment Research (8 papers) and Alzheimer's disease research and treatments (2 papers). Vojislav Pejović is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (11 papers), Dementia and Cognitive Impairment Research (8 papers) and Alzheimer's disease research and treatments (2 papers). Vojislav Pejović collaborates with scholars based in United States, India and Germany. Vojislav Pejović's co-authors include M. L. Miller, Stephen M. Graham, Martin R. Farlow, George T. Grossberg, Robert K. Hofbauer, Suzanne Hendrix, Jess G. Thoene, James L. Perhach, Ricardo Allegri and Facundo Manes and has published in prestigious journals such as Journal of Biological Chemistry, Neurology and Journal of the American Society of Nephrology.
In The Last Decade
Vojislav Pejović
32 papers receiving 517 citations
Peers
Vojislav Pejović
S. Reines United States
Bart Laurijssens United States
Sarah Chau Canada
Mokhtar Isaac United Kingdom
Robert A. Swarm United States
Jae‐Hyeok Heo South Korea
Tomas Müller‐Thomsen Germany
I Degrell Hungary
Martina Zvěřová Czechia
Neda Minakaran United Kingdom
Citations per year, relative to Vojislav Pejović Vojislav Pejović (= 1×)
peers
S. Reines
Countries citing papers authored by Vojislav Pejović
Since
Specialization
Citations
This map shows the geographic impact of Vojislav Pejović's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vojislav Pejović with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vojislav Pejović more than expected).
Fields of papers citing papers by Vojislav Pejović
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Vojislav Pejović. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vojislav Pejović. The network helps show where Vojislav Pejović may publish in the future.
Co-authorship network of co-authors of Vojislav Pejović
This figure shows the co-authorship network connecting the top 25 collaborators of Vojislav Pejović. A scholar is included among the top collaborators of Vojislav Pejović based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vojislav Pejović. Vojislav Pejović is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Atri, Alireza, Suzanne Hendrix, Vojislav Pejović, et al.. (2015). Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis. Alzheimer s Research & Therapy. 7(1). 28–28.
2.
Atri, Alireza, Michael Tocco, Suzanne Hendrix, Vojislav Pejović, & Stephen M. Graham. (2014). Cumulative Benefits of Extended-Release Memantine (28 mg, Once Daily) Across Clinical Domains in Patients With Moderate to Severe Alzheimer's Disease: An Area Under the Curve Analysis. American Journal of Geriatric Psychiatry. 22(3). S120–S121.
3.
Grossberg, George T., Gustavo Alva, Suzanne Hendrix, et al.. (2014). P1‐370: EFFICACY AND TOLERABILITY OF MEMANTINE EXTENDED RELEASE ADDED TO STABLE DONEPEZIL REGIMEN IN INDIVIDUALS WITH MODERATE TO SEVERE ALZHEIMER'S DISEASE: SUBSET ANALYSIS OF A RANDOMIZED CLINICAL TRIAL. Alzheimer s & Dementia. 10(4S_Part_11).
4.
Atri, Alireza, Suzanne Hendrix, Vojislav Pejović, & Stephen M. Graham. (2014). Extended-Release Daily Memantine Provides Increasing Cumulative Benefits Across Clinical Domains Over 24 Weeks in Patients With Moderate to Severe Alzheimer’s Disease: An Analysis of Area Under the Curve (P1.006). Neurology. 82(10_supplement).
5.
Atri, Alireza, Suzanne Hendrix, Vojislav Pejović, et al.. (2014). P4‐352: AREA UNDER THE CURVE (AUC) POOLED ANALYSIS OF FOUR RANDOMIZED CLINICAL TRIALS SHOWS CUMULATIVE BENEFITS OF MEMANTINE‐DONEPEZIL COMBINATION OVER COMPONENT MONOTHERAPIES ACROSS CLINICAL DOMAINS IN ALZHEIMER'S DEMENTIA. Alzheimer s & Dementia. 10(4S_Part_16).
6.
Graham, Stephen M., et al.. (2014). P4‐356: BENEFITS OF EARLY VERSUS DELAYED MEMANTINE ADDITION TO DONEPEZIL MONOTHERAPY IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER'S DISEASE: A POOLED ANALYSIS OF TWO RANDOMIZED TRIALS. Alzheimer s & Dementia. 10(4S_Part_16).
7.
Grossberg, George T., Facundo Manes, Ricardo Allegri, et al.. (2013). The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors. CNS Drugs. 27(6). 469–478.
8.
Graham, Stephen M., Suzanne Hendrix, M. L. Miller, Vojislav Pejović, & Michael Tocco. (2013). Extended-Release Memantine (28 mg, Once Daily) Provides Behavioral Benefits Across a Wide Range of Disease Severity in Patients With Moderate to Severe Alzheimer's Disease: Post Hoc Analysis From a Randomized Trial. American Journal of Geriatric Psychiatry. 21(3). S139–S139.
9.
Saxton, Judith, Robert K. Hofbauer, Mark Woodward, et al.. (2012). Memantine and Functional Communication in Alzheimer's Disease: Results of a 12-Week, International, Randomized Clinical Trial. Journal of Alzheimer s Disease. 28(1). 109–118.
10.
Tocco, Michael, Suzanne Hendrix, M. L. Miller, Vojislav Pejović, & Hamish Graham. (2012). P3‐380: Effects of extended‐release memantine (28 mg, once daily) on language and communication abilities in a randomized trial of patients with moderate‐to‐severe Alzheimer's disease. Alzheimer s & Dementia. 8(4S_Part_16).
11.
Lin, Yu‐Hua, et al.. (2012). Efficacy and tolerability of nebivolol: does age matter? A retrospective analysis of three randomized, placebo-controlled trials in stage I–II hypertension. Therapeutic Advances in Cardiovascular Disease. 6(5). 185–199.
12.
Graham, Stephen M., Suzanne Hendrix, M. L. Miller, Vojislav Pejović, & Michael Tocco. (2012). P3‐386: Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg, once daily) in patients with moderate‐to‐severe Alzheimer's disease. Alzheimer s & Dementia. 8(4S_Part_16).
13.
Tocco, Michael, Suzanne Hendrix, M. L. Miller, Vojislav Pejović, & Stephen M. Graham. (2011). Efficacy of Memantine by Baseline Disease Severity: Post-hoc Analysis of Pooled Trials in Patients with Mild to Moderate Alzheimer's Disease. Journal of the American Medical Directors Association. 12(3). B10–B10.
14.
Tocco, Michael, Suzanne Hendrix, M. L. Miller, Vojislav Pejović, & Stephen M. Graham. (2011). P4‐244: Effects of extended‐release memantine (28 mg/day) on activities of daily living in patients with moderate to severe alzheimer's disease: Post hoc factor analysis of a randomized trial. Alzheimer s & Dementia. 7(4S_Part_23).
15.
Fillit, Howard, Robert K. Hofbauer, Juliana Setyawan, et al.. (2010). Memantine Discontinuation and the Health Status of Nursing Home Residents With Alzheimer's Disease. Journal of the American Medical Directors Association. 11(9). 636–644.e1.
16.
Grossberg, George T., Vojislav Pejović, M. L. Miller, & Stephen M. Graham. (2009). Memantine Therapy of Behavioral Symptoms in Community-Dwelling Patients with Moderate to Severe Alzheimer’s Disease. Dementia and Geriatric Cognitive Disorders. 27(2). 164–172.
17.
Farlow, Martin R., M. L. Miller, & Vojislav Pejović. (2008). Treatment Options in Alzheimer’s Disease: Maximizing Benefit, Managing Expectations. Dementia and Geriatric Cognitive Disorders. 25(5). 408–422.
18.
Pejović, Vojislav, et al.. (2006). Increased Apoptosis in Cystinotic Fibroblasts and Renal Proximal Tubule Epithelial Cells Results from Cysteinylation of Protein Kinase Cδ. Journal of the American Society of Nephrology. 17(11). 3167–3175.
19.
Pejović, Vojislav, Vukić Šoškić, Weihong Pan, & Abba J. Kastin. (2004). Brain proteome of mice lacking the receptors for tumor necrosis factor α. PROTEOMICS. 4(5). 1461–1464.
20.
Pan, Weihong, Victoria Akerstrom, Jian Zhang, Vojislav Pejović, & Abba J. Kastin. (2004). Modulation of feeding‐related peptide/protein signals by the blood–brain barrier. Journal of Neurochemistry. 90(2). 455–461.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by S. Reines Breakdown of academic impact, for papers by Bart Laurijssens Breakdown of academic impact, for papers by Sarah Chau Breakdown of academic impact, for papers by Mokhtar Isaac Breakdown of academic impact, for papers by Robert A. Swarm Breakdown of academic impact, for papers by Jae‐Hyeok Heo Breakdown of academic impact, for papers by Tomas Müller‐Thomsen Breakdown of academic impact, for papers by I Degrell Breakdown of academic impact, for papers by Martina Zvěřová Breakdown of academic impact, for papers by Neda Minakaran